BioSpace News Archive

The San Francisco Bay Area is the world leader in Life Science. Vacaville has been successful at attracting top biotech companies, including Genentech and just recently the Boston-based Agenus.

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received nearly $2M to support a study to evaluate a treatment for volumetric muscle loss (VML), a condition US military surgeons define as the irrecoverable loss of skeletal muscle tissue.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML).

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD).

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced its intention to study its proprietary off-the-shelf T cell technology to develop therapeutic solutions for multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific CD8+ cytotoxic T lymphocytes (CTL).

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on January 18, 2022 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 11,250 shares of Puma common stock to one new non-executive employee.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that the Company has completed a pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA).

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the first patient has been dosed in a Phase 2 clinical trial of OPNT002, nasal naltrexone, for the treatment of Alcohol Use Disorder (“AUD”).

Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder which can spread to other parts of the body.

The drive for accuracy, expandability, and convenience in surgical navigation systems is a key factor creating new avenues in the image guided surgery devices market.